奎硫平治疗阿尔茨海默病伴精神行为障碍对照探究.docVIP

奎硫平治疗阿尔茨海默病伴精神行为障碍对照探究 　【摘要】 目的 探讨奎硫平治疗阿尔茨海默病伴精神行为障碍患者的临床疗效和安全性。 方法 将66例阿尔茨海默病伴精神行为障碍患者随机分为两组各33例，研究组口服奎硫平治疗，对照组口服利培酮治疗，观察8 w。于治疗前及治疗第2 w、4 w、8 w末采用简明精神病量表评定临床疗效、副反应量表评定不良反应。 结果 治疗8 w末，研究组有效率93.9%，对照组为90.9%；治疗2 w末起两组简明精神病量表总分均较治疗前有显著下降，并随着治疗时间的延续呈持续性下降（P＜0.05或0.01）；治疗4 w末研究组简明精神病量表焦虑抑郁因子分显著低于对照组（P＜0.05）；两组不良反应均轻微。 结论 奎硫平治疗阿尔茨海默病伴精神行为障碍效果显著，总体疗效、安全性与利培酮相当。 【关键词】 阿尔茨海默病；精神症状；行为障碍；奎硫平；利培酮；简明精神病量表；副反应量表 【Abstract】 ObjectiveTo explore the clinical efficacy and safety of quetiapine in the treatment of Alzheimers disease(AD) accompaning mental symptoms and behavior disorder. Methods Sixtysix AD patients with mental symptoms and behavior disorder were randomly assigned to two groups of 33 patients each, research group took orally quetiapine and control group did risperidone for 8 weeks. Clinical efficacies were assessed with the Brief Psychiatrie Rating Scale (BPRS) and adverse reactions with the Treament Emergent Symptoms Scale(TESS) before treatment and at the ends of the 2nd,4th and 8th week treatment. Results At the end of the 8th week, effective rates were 93.9% in the research and 90.9% in the control group respectively; since the end of the 2nd week, the total scores of both groups lowered more significantly compared with pretreatment and did continously along with treatment lasting(Plt;0.05 or 0.01);at the end of the 4th week, anxietydepression scores were significantly lower in the research than in the control group(Plt;0.05); adverse reactions of both groups were mild. Conclusion Quetiapine has an evidnet effect in Alzheimer’s disease accompaning mental symptoms and behavior disorder, its global curative effect is equivalent to risperidone, and it has higher safety and better compliance and deserves clinical generalization and utilization. 【Keywords】 Alzheimers disease; psychiatric symptoms; behavioral disorder; quetiapine；risperidone；BPRS; TESS 本研究应用奎硫平（商品名：思瑞康）治疗阿尔茨海默病(AD)伴精神行为障碍与利培酮（商品名：维思通）进行了对照研究,现报告如下。 1 对象与方法 1.1 对象 选取2006年3月～2008年1月在我院老年科住院的AD患者为研究